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ABSTRACT: Understanding the delivered cellular dose of
nanoparticles is imperative in nanomedicine and nanosafety, yet
is known to be extremely complex because of multiple
interactions between nanoparticles, their environment, and
the cells. Here, we use 3-D reconstruction of agglomerates
preserved by cryogenic snapshot sampling and imaged by
electron microscopy to quantify the “bioavailable dose” that is
presented at the cell surface and formed by the process of
individual nanoparticle sequestration into agglomerates in the
exposure media. Critically, using 20 and 40 nm carboxylated
polystyrene-latex and 16 and 85 nm silicon dioxide nano-
particles, we show that abrupt, dose-dependent “tipping points” in agglomeration state can arise, subsequently affecting
cellular delivery and increasing toxicity. These changes are triggered by shifts in the ratio of the total nanoparticle surface
area to biomolecule abundance, with the switch to a highly agglomerated state effectively changing the test article midassay,
challenging the dose−response paradigm for nanosafety experiments. By characterizing nanoparticle numbers per
agglomerate, we show these tipping points can lead to the formation of extreme agglomeration states whereby 90% of an
administered dose is contained and delivered to the cells by just the top 2% of the largest agglomerates. We thus
demonstrate precise definition, description, and comparison of the nanoparticle dose formed in different experimental
environments and show that this description is critical to understanding cellular delivery and toxicity. We further
empirically “stress-test” the commonly used dynamic light scattering approach, establishing its limitations to present an
analysis strategy that significantly improves the usefulness of this popular nanoparticle characterization technique.
KEYWORDS: nanoparticle−biomolecule interactions, agglomeration state, transmission electron microscopy, dynamic light scattering,
dosimetry, nanotoxicology, nanomedicine
Engineered nanomaterials (ENMs) have the potential torevolutionize areas of biomedicine as diverse as cancertherapeutics, antimicrobials, and medical imaging.1,2
However, to achieve these goals, there remains a huge unmet
need to enable translational research through improvement of
our understanding of nanoparticle−biomolecule interactions
and their consequences in terms of the nanoparticle dose that
arrives at the cells. The issue is that even when ENMs are
synthesized in a de novo form that successfully achieves a
desired behavior, they become modified upon introduction to
biological environments through interaction with proteins and
other biological components. According to availability and
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affinity, biomolecules bind onto the surfaces of nanoparticles,
resulting in the formation of a protein corona that modulates
surface properties, chemistry, and charge.3−5 In turn, these
modifications influence the attractive and repulsive forces
operating between nanoparticles in solution, shaping their
potential to collide and form agglomerates. Collectively, these
processes alter the administered dose, leading to the establish-
ment of a “bioavailable dose” under experimental and/or
physiological conditions. Unsurprisingly, this has consequences
for the therapeutic efficacy and toxicity profile of the
nanoparticles that arrive at the cells.6,7
The potential for nanoparticle exposures to cause adverse
effects, alongside the increasing incorporation of potentially
hazardous ENMs into consumer products, necessitates reliable,
high-throughput in vitro assays for nanosafety screening.6,8
However, despite the dramatic increase in nanosafety research
conducted across the past decade, few unequivocal answers
regarding the physical and chemical properties of ENMs that
govern toxicity have been found.9,10 Furthermore, attention is
increasingly becoming focused on the often contradictory
results of similar in vitro studies or corresponding in vitro and in
vivo assessments.6,11 These conflicting findings are thought to
be partially attributable to insufficient ENM characterization in
the biological matrix of the employed test system, where the
aforementioned processes of serum protein-to-particle binding
and agglomeration modify the characteristics of the adminis-
tered dose prior to cellular delivery.3,6,12 Consequently, there is
an urgent need to provide robust biological characterization
data to support, interpret, and translate toxicological findings. It
is realized however that current techniques may be insufficient
to define the bioavailable dose (e.g., when heterogeneous
agglomeration states are formed or the test article is present at
low concentration in a “complex” environment such as serum-
containing cell growth medium).9 New methods for nano-
particle characterization in relevant physiological environments
are therefore required to accurately establish exposure during
nanosafety assessments13−15 as well as to improve the efficacy
and biocompatibility of newly developed nanomedicines.4,7
Nanoparticle agglomeration is most commonly characterized
by dynamic light scattering (DLS). This technique works by
passing laser light through a solution and correlating the light
scatter caused by particulates to their size.16 Whereas DLS
constitutes a robust method for the assessment of “narrow”,
monodisperse particulate size distributions, it is known to
become much less reliable as particulate sizes become
increasingly varied and polydisperse. This occurs intrinsically
as the intensity of the scattered light is proportional to the
sixth-power of the scattering particulate’s diameter (i.e., Isc ∝
d6). A direct consequence of this relationship is that the light
scatter from smaller particulates in a solution quickly becomes
overwhelmed by the scatter signature of any large particulates,
even if the latter are present at extremely low frequency.17−19
Another limitation of DLS is that it is not able to directly
distinguish different types of particulates on the basis of
composition.20 In biological matrices, this means that the light
scatter from serum biomolecules and other biological
componentsin addition to that of the target nano-
particlesall contribute to the size measurements obtained.21
For these reasons it has become common practice to carry out
DLS analysis using just the highest dose tested in a nanosafety
study, as this maximizes the signal from the target nanoparticles
relative to the background signal from biological molecules. In
turn, these characterizations at “top dose” are typically assumed
to be representative for the complete set of exposure
concentrations employed in a toxicological dose−response
assay.22−26
To address the limitations of DLS for the characterization of
nanoparticle dispersions in biological environments, several
studies have employed cryogenic plunge freezing and trans-
mission electron microscopy (TEM) as an alternative technique
for the characterization of agglomeration states.20,27 This
approach relies upon freezing a sample of the nanoparticle
dispersion with sufficient speed such that the liquid phase
vitrifies without significant reorganization of dispersed materi-
al.20 To date, this technique has been used to study the
aggregation of biological molecules28 and polymeric den-
drimers,29 as well as to characterize the agglomeration states
of quantum dot20 and zinc oxide27 nanoparticles in cell culture
media. Critically, this approach circumnavigates the limitations
of “drop-cast” TEM samples whereby a drop of the
nanoparticle dispersion is allowed to air-dry on a TEM grid
prior to imaging. Whereas samples prepared in this manner are
suitable for the characterization of the size, shape, and
composition of individual particles (i.e., primary particle
characterization), they are not an informative or reliable
assessment of agglomeration, as the particulates present are
known to aggregate together as the liquid phase recedes during
evaporation.20,30 It has been shown however that samples
prepared by cryogenic plunge freezing can be warmed under
high vacuum, enabling sublimation of the liquid phase without
disruption of the state of the suspended material.20 Thus, this
approach yields stable, room-temperature samples that are
suitable for imaging and determination of agglomeration state
by routine, high-resolution (<1 nm) bright-field TEM.
Importantly, this “cryogenic snapshot sampling” (CSS)
approach can facilitate the collection of large image sets when
compared to the relative complexity of imaging under full
cryogenic conditions. However, a major limitation of all studies
employing TEM for agglomeration state characterization to
date remains that the data obtained are 2-D, cross-sectional
images of what are ultimately 3-D, agglomerated particulates. In
particular, this places limitations on understanding exactly how
the administered dose is transformed into the bioavailable dose
presented to the cells by the process of individual particle
sequestration into agglomerates.
To this end, here we use 3-D image reconstruction of
cryogenic snapshot sampled agglomerates to calibrate the
number of nanoparticles per agglomerate, permitting precise
definition, description, and comparison of the bioavailable
doses established in different biological environments.
Importantly, we show that shifts in the ratio of the administered
dose to serum biomolecule abundance can trigger abrupt
“tipping points” in agglomeration state that dramatically affect
cellular delivery and subsequent toxicity, challenging the dose−
response paradigm for nanosafety assessments. We further use
the CSS-TEM results to thoroughly “stress-test” the commonly
used DLS method, pinning down its limitations once and for all
to provide an analysis strategy that significantly improves the
usefulness of this popular, high-throughput technique.
RESULTS/DISCUSSION
This study used 20 and 40 nm carboxylate surface-modified
polystyrene-latex (PS) and 16 and 85 nm silicon dioxide (SiO2)
nanoparticles to study the consequences of nanoparticle
agglomeration in terms of the dose of nanoparticles delivered
to human B lymphoblastoid cells (TK6). The TK6 cells were
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chosen because their use is supported by the current
Organisation for Economic Co-operation and Development
(OECD) micronucleus assay test guideline31 (i.e., TG 487);
thus, they represent a widely employed cell line that has been
extensively validated for carrying out this “gold-standard” assay
for the detection of xenobiotic-induced DNA damage. Before
beginning the cell experiments, the manufacturer-supplied stock
nanoparticle solutions underwent thorough physicochemical
characterization (summarized in full in Table S1). Briefly, TEM
was used to define size distributions and showed that all
nanoparticles were smooth and spherical and possessed
amorphous chemical structures. Energy dispersive X-ray
(EDX) analysis confirmed expected elemental compositions
and, importantly for the subsequently presented toxicity results,
ruled out the presence of any contaminants (TEM and EDX
results presented in Figure S1). Analysis by DLS (Table S1,
subsequently presented in full) further showed that stock
nanoparticle solutions were monodisperse and possessed the
high net-negative surface charges expected because of the
carboxylated surface chemistries of the PS nanoparticles and
unbound surface oxygen groups of the SiO2 nanoparticles.
In studying nanoparticle delivery to the cells, the PS
nanoparticles were employed first as they constituted an
excellent model: they are readily internalized by the cells
Figure 1. Tipping points in nanoparticle agglomeration. (a) Average cellular delivery (normalized fluorescence, proportional to particle
number per cell) of 20 nm (crosses) and 40 nm (circles) polystyrene-latex (PS) nanoparticles to TK6 cells grown in normal (NSCM, blue) or
reduced (RSCM, red) serum containing media measured by imaging cytometry after 24 h exposure (5000 cells per replicate; n = 4). (b/c)
Fluorescence micrographs (red = cell membrane, green = nanoparticles) obtained as optical sections by confocal microscopy showing the
increase in cellular dose seen specific to the 20 nm PS/50 nM dose/RSCM combination (b) was caused by a dramatic increase in the quantity
of nanoparticles binding to the outsides of the cells.
Table 1. PS Nanoparticle Agglomeration State and Surface Charge (Zeta Potential) Characterization by Dynamic Light
Scattering across Dose and Serum Environments (NSCM/RSCM = Normal/Reduced Serum Containing Media) Using the
Cumulants (“Z-Average”) Analysis Approacha
aA dramatic increase in agglomerate size was indicated for the 50 nM dose of 20 nm PS in RSCM, but the accompanying polydispersity index (PdI)
was above the reliability threshold for cumulants-based analysis (indicated, red).
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(Figure S2), produce a stable fluorescence intensity (Figure
S3), are nontoxic to the cells, permitting accurate quantification
of the full range of delivered cellular doses after exposure
(Figure S4), and are neutrally buoyant (density = 1.05 g/cm3),
minimizing sedimentation and optimizing delivery to the
suspended-cell population. Subsequently, the SiO2 nano-
particles were used, as they represent a commonly tested
nanosafety test material due to exposure concerns arising from
their incorporation in polishes, adhesives, varnishes, and
photocopier toner and their use as food-stabilizing agents and
Figure 2. Characterizing PS nanoparticle agglomeration state using cryogenic snapshot sampling and transmission electron microscopy (CSS-
TEM). Tiled electron micrographs (a/b/d/e, 20 nm PS; g/h, 40 nm PS) from the CSS-TEM studies showing nanoparticle agglomeration
states 1 h after dose administration at 10 or 50 nM in normal (NSCM, blue) or reduced (RSCM, red) serum containing media (150
micrographs yielding ∼1300−5000 agglomerates per sample). The change in cellular delivery observed optically (Figure 1b) for the 50 nM
dose of 20 nm PS in RSCM is seen to coincide with an abrupt change (e) to much larger agglomerates. (c/f/i) Agglomerate area distributions
constructed by image analysis of the CSS-TEM data.
ACS Nano Article
DOI: 10.1021/acsnano.7b03708
ACS Nano 2017, 11, 11986−12000
11989
Figure 3. Modulation of the delivered cellular dose of 20 nm PS nanoparticles by agglomeration. (a/b) The areas and volumes of five
agglomerates of varying size were measured by rotation (b) using electron micrographs collected by ∼100 image tilt-series experiments (see
Video S1 for full resolution view). (a) These measured data (circles) empirically validate the scaling model used to transform the 2-D CSS-
TEM agglomerate area data into estimated agglomerate volume (line = transformed CSS-TEM data). (c/d) Estimated agglomerate volume
distributions obtained by applying the scaling model to the 2-D CSS-TEM data for administered nanoparticle doses of 10 or 50 nM in normal
(NSCM, blue) or reduced (RSCM, red) serum containing media. (e/f) Cellular fluorescence distributions, linearly related to the volume of
the nanoparticle dose per cell, (i.e., directly comparable to c/d) constructed from the combined imaging cytometry data shown in Figure 1a
(histograms with overlaid outlines). Below the distributions (g/h), sample fluorescence micrographs (green = nanoparticles) from the
cytometer corresponding to the indicated intensity bins are shown. Cell-to-cell variability in the delivered dose (e/f) increased dramatically
with increasing agglomerate size heterogeneity (c/d).
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cosmetic additives.32,33 Critically, they also represent a
nanoparticle type that has produced conflicting results when
the findings of similar in vitro studies or corresponding in vitro
and in vivo assessments have been compared.32
As serum concentration is dynamic in vivo34−36 and the
concentration of supplemental serum used in vitro is known to
affect nanosafety test outcomes, the use of more than one
concentration during nanosafety hazard assessment has been
recommended.37−40 We therefore began by evaluating the
cellular delivery of the PS nanoparticles in either normal (10%)
(NSCM) or reduced (2%) (RSCM) serum containing cell
culture media.
Characterizing Cellular Delivery and 2-D Agglomer-
ation State. Using high-throughput imaging cytometry, the
delivered cellular dose of 20 or 40 nm PS nanoparticles after 24
h of exposure in the NSCM or RSCM serum environments is
shown in Figure 1a. For both the 20 nm and 40 nm PS, this
increases more or less linearly, as expected, and is independent
of serum environment over the 0−30 nM dose range.
Interestingly, however, the 20 nm PS exposure at 50 nM in
RSCM resulted in a marked, nonlinear increase in cellular dose.
Confocal microscopy (Figure 1b/c) showed this change was
caused by a dramatic increase in the quantity of nanoparticles
binding to the outside of the cells relative to those internalized
(further confocal micrographs for all nanoparticle/serum
combinations presented in Figure S5). In an effort to
understand why this sudden transformation occurred, DLS
was used to assess nanoparticle agglomeration states and
surface charges (Table 1). The results proved difficult to
interpret however since there was little concurrency in 20 nm
PS size measurements across serum environments, even for the
10 nM doses that showed highly similar cellular delivery in both
media types. A dramatic increase in agglomerate size (∼650
nm) relative to all other 20 nm PS measurements (<125 nm)
was indicated by DLS for the 50 nM dose in RSCM, but the
accompanying polydispersity index (PdI) was high enough
(0.61) to suggest a heterogeneous size distribution unsuitable
for this type of averaged, cumulants-based analysis.41 Thus, as
these “Z-average” DLS resultswhich are typical of those often
employed by nanosafety studieswere of questionable utility
for providing further insight into the findings of the delivered
dose study, the state of PS nanoparticle agglomeration was
further investigated using cryogenic snapshot sampling−
transmission electron microscopy (CSS-TEM) and image
analysis20 (method explained in Figure S6).
At administered doses of 10 nM, the 20 nm PS
agglomeration states captured by CSS-TEM across the
NSCM and RSCM environments were visually very similar
(Figure 2a/b), and the resultant size distributions of
agglomerate area produced by image analysis were nearly
identical (Figure 2c). In contrast, the 20 nm PS agglomeration
states established from administered doses of 50 nM were seen
to markedly differ across serum environments (Figure 2d/e)
with large, sparsely distributed agglomerates forming in RSCM
in a manner specific to this dose and serum combination
(Figure 2e). Interestingly, however, this visually striking change
to larger agglomerates in RSCM is not immediately apparent in
the comparison of the area size distributions (Figure 2f). Here,
the size distribution in RSCM appears anomalous because of a
low quantity of agglomerates present, not because of an increase
in agglomerate size, as is visually expected. In keeping with the
findings of the delivered cellular dose (Figure 1) and DLS
studies (Table 1), CSS-TEM-based comparisons of the 40 nm
PS show agglomeration states established from 10 nM
administered doses across serum environments were highly
similar (Figure 2g−i).
3-D Agglomerate Characterization Sheds Light on
Delivery Heterogeneity. When considering the size
distributions presented by agglomerate area in Figure 2, it is
important to note that these were constructed using 2-D cross-
sectional image information without taking into account the
true 3-D geometry of each agglomerate. This is of importance,
as this 2-D view presents an impediment to understanding
exactly how the dose administered is transformed into the
bioavailable dose presented to the cells by the sequestering of
individual nanoparticles into 3-D agglomerates. Thus, to obtain
a more complete description of how identical, 50 nM
administered doses of 20 nm PS established such different
bioavailable doses across serum environments, the cross-
sectional area data were transformed using a power law
Figure 4. Transformation of the 50 nM administered dose of 20 nm PS by nanoparticle agglomeration. (a) Estimated total amount of
nanoparticle material present at each agglomerate size in normal (NSCM, blue) or reduced (RSCM, red) serum containing media calculated
as the product of agglomerate population percentage and agglomerate volume. (b) Cumulative distribution function of the administered dose
in each serum environment, proceeding from the largest to the smallest size fraction of agglomerates. The arrow indicates that ∼90% of the 50
nM administered dose was sequestered into just the top 2% size-fraction of largest agglomerations in RSCM, whereas in NSCM, only ∼50% of
the administered dose was contained within this same agglomerate size-fraction.
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Figure 5. DLS stress-testing: 20 nm PS and 40 nm PS agglomerate hydrodynamic size distributions by number (stars) were extracted from the
DLS study (Table 1) and compared to agglomerate Feret diameter measurements directly measured by CSS-TEM (circles). (a/b/g) For the
results collected using water as a dispersant (i.e., in “as-manufactured” dispersant), primary size distributions of individually measured
nanoparticle diameters obtained from drop-cast TEM micrographs were also included (green lines) to provide a point of reference for the size
of individual nanoparticles relative to agglomerates (i.e., primary size controls). Size distributions were measured 1 h after dose administration
at 10 nM (left; a/c/e/g/h) or 50 nM (right; b/d/f) in water (black), normal (NSCM, blue), or reduced (RSCM, red) serum containing media.
DLS size distributions for the NSCM and RSCM alone (dashes) were included as media controls to ensure that the target nanoparticles were
reliably detected against the light-scattering background of serum molecules.
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model (i.e., volume = agglomerate area ^ scaling factor) to yield
a description of each agglomerate’s volume (Figure 3a). A
scaling factor of 1.33 was empirically defined by comparison of
the transformed 2-D area data to measurements taken from a
series of 3-D agglomerate reconstructions, obtained by rotating
(Figure 3b) cryogenic snapshot sampled agglomerate speci-
mens of a range of sizes within the TEM and acquiring their
dimensionality from ∼100 image “tilt series” (full resolution tilt
series shown in Video S1/all tilt-series experiments detailed in
full in Figure S7). These transformed data were then used to
produce agglomerate volume distributions for the 10 and 50
nM doses of 20 nm PS across the NSCM and RSCM serum
environments (Figure 3c/d). Specific to the 50 nM/RSCM
combination (Figure 3d), this revealed a “tail” of extremely
large agglomerates (>108 nm3) that were hidden in the original
agglomerate area distributions (Figure 2f) due to a low
frequency of occurrence (<∼2%). As the fluorescence intensity
of the PS nanoparticles is proportional to their volume (shown
in Figure S8), these agglomerate volume distributions (Figure
3c/d) should (and indeed do) correlate to the delivered cellular
dose measurements obtained optically by imaging cytometry
(Figure 3e/f). This comparison demonstrates the critical
importance of this small subpopulation of very large
agglomerates in driving (1) the overall increase in cellular
delivery (Figure 1b) and (2) the >10-fold cell-to-cell variability
in the delivered dose noted specific to the “extreme”
agglomeration state formed by the 50 nM dose/RSCM
combination (Figure 3f/h).
Impact of Agglomeration State on Nanoparticle
Dosimetry. To further understand the extreme agglomeration
state formed from the 20 nm PS/50 nM dose/RSCM
combination, the total amount of nanoparticle material (i.e.,
the product of agglomerate population % and agglomerate
volume) was evaluated for each agglomerate size (Figure 4a).
The results highlight a marked serum-related difference in the
proportion of the 50 nM administered dose contained within
large agglomerates (cross-sectional areas >105 nm2). In turn,
the cumulative distribution function of the administered dose,
proceeding from the largest to the smallest size-fraction of
agglomerates, shows that in RSCM the largest 2% of
agglomerates contained and delivered 90% of the administered
dose, while in NSCM this same 2% size-fraction contained just
50% of the administered dose (Figure 4b). This means that the
50 nM administered dose of 20 nm nanoparticles formed a
bioavailable dose of ∼2 nM of agglomerates with a mean
diameter of <60 nm in NSCM. In contrast, a dose of just ∼3
pM was established from agglomerates with a mean diameter of
>500 nm in RSCM. Thus, this explains the extensive
nanoparticle cell surface binding that occurred when the cells
were exposed to the 20 nm PS/50 nM dose/RSCM
combination (Figure 1b), suggesting that the majority of the
administered nanoparticle dose was contained in agglomerates
too large to be internalized by the cells.
Stress-Testing the DLS Results. While CSS-TEM is a
high-resolution technique that is well suited to defining the
specifics of nanoparticle agglomeration in biological matrices,
its low-throughput, specialist nature limits its applicability for
the rapid nanosafety screening of ENMs. We therefore
compared the direct, agglomerate size measurements from
the CSS-TEM studies to the full DLS size distributions (by
number, extracted from results presented in Table 1) to permit
a thorough “stress-testing” of the conditions under which the
commonly used DLS technique can reliably inform on
agglomerate state. For CSS-TEM, Feret diameter measure-
ments were extracted for this comparison42 due to the inherent
weighting of DLS toward the longest dimension of a scattering
Figure 6. Using DLS alone to detect abnormal agglomeration states: BASF Levasil silicon dioxide nanoparticles (SiO2). (a/c) 16 nm SiO2 and
(b/d) 85 nm SiO2 hydrodynamic size distributions by number (stars) were extracted from the DLS studies. (a/b) For the results collected
using water as a dispersant (i.e., in “as-manufactured” dispersant), primary size distributions of individually measured nanoparticle diameters
obtained from drop-cast TEM micrographs were also included (green lines) to provide a point of reference for the size of individual
nanoparticles relative to agglomerates (i.e., primary size controls). Size distributions were measured 1 h after dose administration at 73 nM
(16 nm SiO2) or 0.5 nM (85 nm SiO2) in water (black), normal (NSCM, blue), or reduced (RSCM, red) serum containing media. DLS size
distributions for the NSCM and RSCM alone (dashes) were included as controls to ensure that the target nanoparticles were reliably detected
against the light-scattering background of serum molecules.
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body (i.e., due to Isc∝ d6, see introduction). Given the wide
dynamic range of PS agglomerate sizes known to be established
in the NSCM/RSCM environments, size distributions were
plotted on double-log axes to facilitate visualization and
comparison. Negative, “media control” data for the NSCM/
RSCM media in the absence of nanoparticles were included in
all DLS analyses to ensure that the nanoparticles were being
reliably detected and/or distinguished against the background
light scatter from the serum molecules. For the size
distributions recorded in water (the manufacturer’s dispersant
for all stock nanoparticle solutions) measurements of individual
nanoparticle diameters (i.e., primary size distributions) from
drop-cast TEM samples were also included to inform on stock
colloid stability and to provide a point of reference for the size
of individual nanoparticles relative to agglomerates.
Comparison of the primary size, DLS, and CSS-TEM results
for the 20 nm PS in water for both 10 and 50 nM administered
doses (Figure 5a/b, respectively) showed strong agreement in
the measurements recorded across all three techniques. This is
encouraging, as these conditions (i.e., monodisperse, free from
the influence of other scattering particulates) should be where
DLS performs optimally. Comparison of the primary size
distributions (i.e., individual particle measurements) to the
agglomerate size distributions (i.e., measured by DLS or CSS-
TEM) also confirmed the colloidal stability of these aqueous
solutions, showing that less than ∼10% of particulate size-
fractions occupied sizes greater than the maximum primary
particle size. In NSCM at 10 nM concentration (Figure 5c), the
20 nm PS were undetectable against the serum protein
background by DLS, as shown by the size distribution’s direct
overlay with the NSCM media control and by comparison to
the true size distribution defined by CSS-TEM. When the
nanoparticle dose was increased 5-fold to 50 nM however
(Figure 5d), both serum proteins (first peak from left,
identifiable against the NSCM control) and the target
nanoparticles (second peak, aligned with CSS-TEM) were
detectable by DLS in the NSCM environment. Similarly, when
the serum concentration was reduced to 2% (i.e., RSCM), the
10 nM nanoparticle dose (Figure 5e) was detectable against the
RSCM background. Finally, the abrupt change to an extreme
state of agglomerationnoted specific to the 20 nm PS/50 nM
dose/RSCM combinationwas detectable by DLS (Figure 5f),
but the abundance of large agglomerates can be seen to be
overestimated by comparison to the CSS-TEM distribution.
Contrastingly, comparison of the 40 nm PS results (Figure 5g/
h) obtained across measurement techniques in water, NSCM,
or RSCM dispersants showed little evidence of any changes in
agglomeration state from that of the stock, aqueous solution.
Employing Lessons Learned in DLS Interpretation:
SiO2 Nanoparticles. To test the lessons learned in DLS
interpretationaided by growth medium and primary size
controlsFigure 6 presents agglomeration state character-
izations for the 16 and 85 nm SiO2 nanoparticles where
corresponding CSS-TEM analyses were not made. In water,
excellent alignment between the primary size distributions and
the DLS results was observed for both nanoparticle sizes
(Figure 6a/b). Comparison of the 16 nm SiO2 DLS data across
the NSCM and RSCM serum environments (Figure 6c)
showed very different agglomeration states formed, with much
larger agglomerates identified in RSCM. Here, the distribution
in NSCM also presented two distinct peaks, the first (from left)
of which can be attributed to serum particulate scatter by
comparison against the NSCM media control and because it
falls below the known lower limit of the particles’ primary size
(∼10 nm) (Figure 6a). Similarly, whereas the 85 nm SiO2
agglomerate size distributions by DLS (Figure 6d) were quite
similar across serum environments, the distribution in RSCM
shows two distinct peaks. Again, comparison of this first peak to
the primary size distribution (Figure 6b) shows it falls below
the lower limit of the nanoparticles’ primary size (∼40 nm) and
thus cannot represent the target nanoparticles.
Consequences of Serum-Dependent SiO2 Agglomer-
ation: Cell Viability and Cellular Delivery. Following up on
the SiO2 agglomeration state characterizations in each serum
environment (Figure 6), the potential for any concomitant,
serum-dependent differences on cellular toxicity arising upon
exposure to the SiO2 nanoparticles was investigated. Using test
methods previously optimized in-house for nanoparticle test
materials,21,38 TK6 cell viability after 24 h exposure was
assessed by relative population doubling analysis. Alongside in
duplicated, satellite cell cultures, the potential for chromosomal
damage was also assessed using the binucleated cell micro-
nucleus assay (alternative mass/volume and surface area dose
metrics provided in Table S2). When considering the 16 nm
SiO2 results, it was immediately apparent that administered
doses of >15 nM had a heightened effect on cell viability when
administered in RSCM compared to in NSCM (Figure 7a).
Employment of quantitative dose−response modeling (i.e.,
“benchmark dose” nonlinear regression analysis) indicated that,
as a result of this serum-dependent effect, the dose of 16 nm
SiO2 required to cause a 50% decrease in cell viability was
approximately 2.5 times less in the RSCM environment
compared to that in NSCM (analysis presented in Figure
S9a). In contrast, administered doses of the 85 nm SiO2 caused
similar dose-dependent decreases in cell viability regardless of
NSCM or RSCM serum environment (Figure 7b). This
observation was also supported by the dose−response
modeling, which rejected serum environment as an influential
covariate, showing that all 85 nm SiO2 cell viability data,
regardless of serum environment, were well-described by a
single dose−response model (analysis presented in Figure
S9b). In keeping with previous findings,33 micronucleus test
results showed that both the 16 nm SiO2 and the 85 nm SiO2
were weakly genotoxic, with exposures to the 50% cytotoxicity
cutoff causing maximum micronucleus inductions of around
∼2.5-fold (bars; Figure 7a/b).
To unravel the serum-dependent effects underlying the cell
viability studies, the cellular delivery of the SiO2 nanoparticles
was investigated by sectioned-cell TEM, with supporting EDX
analyses used to unequivocally identify the delivered dose of
nanoparticles (false-colored green; Figure 8; a further ∼20
images for each dose and serum environment alongside EDX
spectra are also presented in Figures S10−S13). Similar to the
20 nm PS findings at 50 nM, the results highlighted a dramatic
increase in the quantity of 16 nm SiO2 nanoparticles found
bound to cell membranes in RSCM compared to NSCM
(Figure 8a/b). In contrast, the delivered cellular doses of 85 nm
SiO2 remained similar regardless of serum environment (Figure
8c/d). Taken in combination, it is thus again evident that
serum-dependent differences in the agglomeration state of the
16 nm SiO2successfully detected here by DLS alone (Figure
6c)underpin the differences in cellular delivery (Figure 8a/b)
and subsequent toxicity (Figure 7a) observed specific to
administered doses of 16 nm SiO2 above 15 nM.
Dependency of Agglomeration State on Dose and
Serum Availability. The central tenet of toxicity testing is that
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the quantified biological response indicates the potency of the
toxin at the administered dose (i.e., “the dose makes the
poison”). However, since the particokinetics of nanoparticle
dispersions are time and environment dependent, the
administered form of the material is not necessarily the same
as that encountered by the target cell.3,13,43 Consequently,
dose−response profiling has the potential to become
misleading as the measured response becomes a reaction to
an inaccurately quantified dose.43,44 Here, the 20 nm PS and 16
nm SiO2 results provide a vivid example of the difficulties that
can arise. When considering the relationship between the
administered and delivered doses for typical concentrations of
test materials (0−73 nM), abrupt “tipping points” emerged at
which the administered nanoparticle dose suddenly changed
agglomeration state, showing a dynamic interplay between the
surface area of the dose and the availability of serum.10 These
findings suggest that excess serum can promote nanoparticle
dispersity, perhaps because a surface coating of serum facilitates
steric hindrance between nanoparticles, inhibiting their collision
to form agglomerates.45,46 In this scenario, excess serum plays a
surface-passivating role,10 stabilizing the nanoparticle dispersion
and preventing agglomeration until, with increasing dose or
decreasing serum concentration, serum abundance becomes
limited, triggering a tipping point change in agglomeration
state.
Whereas the results thus indicate a general link between the
administered dose, the availability of serum, and the onset of
changing agglomeration states, closer scrutiny shows that a
simple, predictable relationship between the total surface area of
an administered dose and the onset of tipping point changes in
agglomeration did not occur. More specifically, it is observed
that exposures to the 40 nm PS and 85 nm SiO2 nanoparticles
failed to elicit a tipping point, despite the utilization of
administered doses with equal or greater total surface areas to
those that caused the effect with the smaller, yet otherwise
compositionally identical 20 nm PS or 16 nm SiO2 (shown
diagrammatically in Figure S14). It is suggested that this
disparity likely reflects the complexity of factors underpinning
these tipping points, resulting in a tendency for them to be
challenging to predict from a theoretical basis. For example, the
failure of the larger nanoparticle size-types (i.e., the 40 nm PS
and 85 nm SiO2) to elicit a tipping point may further indicate
the importance of size-specific diffusion speeds and therefore
particle−particle collision energies in agglomerate forma-
tion.47,48 With specific regard to the absence of a tipping
point during the 40 nm PS exposures, it is observed that even at
doses with equivalent surface areas to those where 20 nm PS
doses elicited the effect, the fact that the two particle types
possess different densities of surface carboxyl groups (see
Methods) will confer different abilities to bind serum and
trigger the tipping point.
The data therefore indicate that the inherent unpredictability
of these tipping points necessitates the robust, empirical
techniques presented here to permit successful detection. This
is because any sudden onset in nanoparticle agglomeration has
the effect that the test material changes abruptly midassay from
a nano- to a microparticulate. This not only decouples the
administered dose from that delivered to the cells49 but also
dramatically alters nanoparticle−cell interactions such that the
quantity, cell-to-cell variability, and localization (e.g., cell-
membrane-bound versus internalized) of the delivered dose all
abruptly change. Successful detection of these tipping points is
therefore essential, as, once triggered, these changes invalidate
the standard dose−response framework from both directions as
the dose is inaccurately quantified and the nature of the
exposure driving the biological response changes midassay.
CONCLUSIONS
Understanding the transformation of nanoparticle dose under
relevant physiological and/or experimental conditions is
essential for the efficacy of nanomedicines, as well as for all
in vitro, in vivo, and ecological testing strategies if nanosafety
evaluations are to become more reliable, realistic, and
predictive.13−15 The results herein show study design
reconsiderations for nanoparticle testing are required in vitro
as we challenge the usual assumptions that (1) agglomeration
state characterization for a single dose adequately represents all
exposures in an employed dose range;22−26 (2) administered
dose can be used to compare toxicity results across cell lines,
growth media,22,25 and serum combinations23,24 without full
consideration of the impact these different environments have
on cellular delivery; and (3) it is sufficient to define adverse
response as an average from a treated cell population without
consideration of cell-to-cell variability in dose delivery.50−52
We assert that strategies do exist to tackle these challenges. If
the traditional paradigm of measuring averaged cell population
Figure 7. Impact of the SiO2 nanoparticles on cell viability and
DNA damage in normal or reduced serum containing media. TK6
cells were exposed (24 h) to doses of (a) 16 nm SiO2 or (b) 85 nm
SiO2 in normal (NSCM, blue) or reduced (RSCM, red) serum
containing growth medium (n = 6, error bars = SD). The impact of
exposure on cell viability (cell growth/cytotoxicity) was assessed in
terms of relative population doubling (lines) relative to unexposed
control cultures. DNA damage (bars) was assessed via binucleated
cell micronucleus frequency until cell viability decreased below
50%. (●, ⧫,★) Response statistical significance relative to undosed
control at p < 0.05, p < 0.01, and p < 0.001, respectively. (a) At
administered doses of >15 nM, the 16 nm SiO2 showed distinctly
different trends in cell viability across serum environments. (b) In
contrast, cell viability data for the 85 nm SiO2 exposures remained
highly similar regardless of serum environment.
ACS Nano Article
DOI: 10.1021/acsnano.7b03708
ACS Nano 2017, 11, 11986−12000
11995
responses is to be maintained, it is clear that quantification of
the bioavailable dose for the full set of experimental exposures
will be required. To this end, we demonstrate the reliability of
the popular, high-throughput DLS approach can be significantly
improved if the user examines log-scaled number distributions
and includes primary size and growth medium controls. Our
findings show that while DLS is inaccurate for the absolute
quantification of agglomeration state, it can identify tipping
points in agglomeration state and the concomitant illegitimacy
of a nanosafety dose−response profile. Where DLS fails (e.g.,
small nanoparticles/low concentrations of test-material/high
environmental biomolecule concentrations) or where detailed
specifics of agglomeration dynamics are required (e.g., to better
understand the dosimetry of nanomedicines) we further
demonstrate the 3-D CSS-TEM approach. Although this is
ultimately lower-throughput and requires specialized equip-
ment, we show it is extremely well-suited to provide high-
resolution insights into the precise nature of nanoparticle
agglomeration under conditions where current techniques fail.
An alternative and previously advocated approach to
addressing the issues raised here involves the employment of
dispersion strategies to create monodisperse nanoparticle
suspensions in vitro.6,12,53,54 Such approaches have been
shown to dramatically improve the reproducibility of in vitro
nanosafety results6 and also to permit the accurate computa-
tional modeling of nanoparticle cellular delivery.6,53−55 It is also
thought that the latest generation of these dosimetry models
offer the potential to accurately predict the delivery of
polydisperse nanoparticle dispersions, if equipped with
accurate, empirical descriptions of agglomeration state.54 For
Figure 8. Cellular delivery of the SiO2 nanoparticles in normal or reduced serum containing media. To understand the cellular delivery of the
SiO2 nanoparticles in normal (NSCM, blue) and reduced (RSCM, red) serum environments, electron microscopy of sectioned cells was
carried out 24 h after exposure, with energy dispersive X-ray (EDX) analysis used to identify the nanoparticles (false-colored green). (a/b)
Cellular delivery of the 16 nm SiO2 (73 nM dose) varied dramatically across serum environments, with much greater quantities of
nanoparticles observed bound to cell membranes in RSCM (b) when compared to NSCM (a). In contrast (c versus d), cellular delivery of the
85 nm SiO2 (0.5 nM dose) remained highly similar regardless of serum environment. Scale bars = 1 μm.
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this purpose, it is suggested that the 3-D CSS-TEM approach
presented here is well-suited to provide the required data, thus
enabling the further development and stress-testing of these
essential exposure characterization tools.
Ultimately, the data presented in this report demonstrate that
such progress toward fully understanding the cellular delivery of
polydisperse nanoparticle exposures is essential. This is because
outside of the in vitro domain it remains that real-world human,
environmental, and medical nanoparticle exposures are unlikely
to be monodisperse and hence will be cellularly presented as
the complex and dynamic agglomerated size ranges discussed
herein. We therefore demonstrate precise quantification,
definition, and comparison of the bioavailable dose established
by complex agglomeration processes and show that this
description is critical to understanding cellular delivery, uptake,
and toxicity. Importantly, our approaches are broadly applicable
to other biological matrices where existing technologies and
current understanding of test-material and nanomedicine
dosimetry fail.
METHODS/EXPERIMENTAL
Primary Nanoparticle Physicochemical Characterization.
Nanoparticle samples were prepared for primary size (i.e., individual
particle) characterization by drop-casting aqueous solutions onto glow-
discharge-treated standard holey carbon TEM support grids (Agar
Scientific, Stansted, UK) at the concentrations indicated in the text.
TEM in conjunction with EDX spectroscopy was used to determine
size, shape/morphology, crystallinity, composition, and purity. Nano-
particle primary size distributions were constructed from individual
nanoparticle diameter measurements (n > 120) made from bright-field
electron micrographs using the ImageJ software.56
Cell Preparation and Nanoparticle Exposures. TK6 human B
lymphoblastoid cells (#95111735, Health Protection Agency) were
maintained in RPMI 1640 medium (#32404014, ThermoFisher)
supplemented with 1 mM glutamine and either normal (10%)
(NSCM) or reduced (2%) (RSCM) horse serum (#16050122,
ThermoFisher). Cell cultures were maintained in an atmosphere of
5% CO2 in humidified air at 37 °C. Prior to nanoparticle exposure,
independent cell populations were established at 2 × 105 cells/mL in
T25 culture flasks. Exposures to the 20 nm PS or 40 nm PS
nanoparticles were to 20 or 40 nm carboxylate surface-modified
(surface charge densities = 0.7152 and 3.0420 mEq/g, respectively),
yellow-green fluorescent (excitation/emission = 505/515 nm),
neutrally buoyant (density = 1.05 g/cm3) FluoSphere polystyrene
latex nanoparticles (#F8787 and #F8795, ThermoFisher). Exposures
to the 16 nm SiO2 or 85 nm SiO2 were to 16 or 85 nm amorphous
silicon dioxide (SiO2) (density = 2.65 g/cm
3) nanoparticles (Levasil
200 or Levasil 50, BASF). Flasks were returned to the incubator for the
24 h exposure period. Further mixing during exposure was not
employed in an effort to (a) replicate the typical exposure approach
commonly used by the majority of in vitro nanosafety studies and (b)
to ensure cell divisioncritical to the success of the micronucleus
assaywas not inadvertently disrupted. Dose was increased until
either a 50% reduction in cell viability was reached (i.e., according to
OECD test guideline 487)31 or until the maximum dose permitted by
the stock nanoparticle solution’s concentration was reached.
Immediately after exposure, cells were transferred to 15 mL conical
tubes (#430791 Sigma), pelleted by centrifugation (10 min; 129g),
and the nanoparticle-containing supernatant was fully aspirated by
pipet. The cell pellet was then resuspended by flicking the tube prior
to repeating this process twice via two further wash steps each using 12
mL of prewarmed phosphate-buffered saline (PBS) (37 °C). After
washing, cells were immediately prepared for characterization of
cellular delivery by either imaging flow cytometry or sectioned-cell
TEM.
Imaging Flow Cytometry. Cells were resuspended in PBS at 1 ×
107 cells/mL concentration prior to image collection using an IS100
imaging flow cytometer (Amnis Corporation). A 405 nm wavelength
laser was used to excite PS nanoparticle fluorescence, which was
collected in the 505−560 nm spectral detection range. A sample of
10 000 cell images was taken from each cell population (n = 4) and
analyzed using the manufacturer’s IDEAS software. Two-dimensional
plots of cell area and aspect ratio were used to isolate single, viable
cells with this population further refined to cells within the focal plane
by linescan gradient. This process reduced the analyzed cell
populations to ∼5000 cells; hence ∼2 × 104 cells total were assessed
per dose across the four independent experimental replicates. The
delivered nanoparticle dose per cell was measured as the integrated
fluorescence intensity within the bright-field delineated area of each
cell.
Confocal Microscopy. Microscopy coverslips were preincubated
in poly-L-lysine (1 mg/mL) to facilitate attachment of fixed (4%
paraformaldehyde), pre-exposed cells. A 5 μg/mL concentration of
Alexa Fluor 633 conjugated wheat germ agglutinin (W21404,
ThermoFisher) in 1% Hank’s balanced salt solution (HBSS)-buffered
bovine serum albumin was used to label cell membranes (15 min
incubation). To label the cytoskeleton, cell-loaded coverslips were first
permeabilised with 0.1% Triton X-100 (3 min) prior to 15 min of
incubation with 33 nM HBSS-buffered Alexa Fluor 594 conjugated
phalloidin (A12381, ThermoFisher). Coverslips were then washed
three times in fresh HBSS and mounted on slides in glycerol-based
mounting medium with or without Hoechst 33342 nuclear stain (1
μg/mL). Images were recorded as 2-D optical sections and as 3-D
reconstructable “Z-stacks” using an LSM-710 confocal microscope
equipped with a 40×/1.3NA oil immersion objective (Carl-Zeiss).
PS Nanoparticle Fluorescence Properties and pH Stability.
To determine if fluorescence was a function of nanoparticle volume,
the photon luminescence of the compositionally identical 40 nm PS
and 20 nm PS was compared at equal number concentrations (i.e., 20
nM, aqueous solutions), confirming the expected 8-fold volume-based
relationship. Fluorescence stability was further assessed in water
(manufacturer’s dispersant), NSCM, and RSCM, as well as in three
previously described57 incubation buffers designed to mimic the
different pH stages of the endosomal−lysosomal life cycle: the pH 7.0
buffer was phenol red free RPMI 1640 (#32404014, ThermoFisher),
while the pH 5.5 and pH 4.5 buffers were combinations of 0.1 N
sodium acetate and 0.1 N acetic acid (pKA 4.76). Nanoparticle
fluorescence was quantified using a QuantaMaster spectrofluorimeter
(Photon Technology International) as the integrated photon
luminescence across the spectral detection range (505−560 nm)
used in the cell-delivery study by imaging cytometry.
Agglomerate Analysis. PS nanoparticles were added to T25
culture flasks containing NSCM or RSCM but absent of cells. Flasks
were returned to the incubator for 1 h to allow agglomeration
processes to occur prior to characterization by CSS-TEM or DLS.
Continuous carbon films supported by copper TEM grids (#AGS160-
4, Agar Scientific) were glow discharged at 5 kV for 30 s before loading
with 3.5 μL droplets of the nanoparticle−media suspension inside the
preparation chamber of the Mark IV Vitrobot (FEI), which was
maintained under cell culture conditions at 37 °C and 95% humidity.
A 30 s delay was applied to ensure the droplet was equilibrated before
blotting and vitrification through rapid plunge freezing into liquid
ethane. Prepared grids were transferred into a vacuum desiccator and
then allowed to warm to room temperature, thereby preserving
particle agglomeration states.20 Samples were then imaged by bright-
field TEM (150 micrographs yielding ∼1300−5000 agglomerates per
dose/serum sample). Agglomerates were manually segmented to
binary masks and automatically measured using ImageJ (detailed
methodology presented, Figure S6). Five ∼100-image tilt-series
sequences of CSS sampled agglomerates with sizes spanning the
range measured in the zero-tilt CSS-TEM study (i.e., one agglomerate
per each size fraction on the order of 0.1, 1, 2, 3, and 4 μm in
diameter) were collected to assess 3-D morphology (presented in
Figure S7/Video S1). Bright-field TEM images were collected at 1
degree intervals over the largest accessible tilt range for each individual
agglomerate. The data were reconstructed using the TomoJ58 plugin
for ImageJ. All five tilt series show the agglomerates to be flattened,
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presumably due to the blotting step in the CSS preparation for TEM.
Normalized agglomerate volumes were thus obtained by multiplying
the imaged agglomerate area (normalized to the area of the smallest
agglomerate) by its thickness estimated from the tilt-series
reconstruction (and normalized to the thickness of the smallest
agglomerate), i.e., assuming the agglomerates were all plate-like.
Dynamic Light Scattering. The dynamic viscosity of RSCM and
NSCM at 37 °C was determined as 0.7223 and 0.7572 cP, respectively,
by the U-tube viscometer method,59 with both possessing a measured
refractive index of ∼1.34. To obtain informative size data, care was
taken to reproduce the exact process used to expose cells; thus
dispersions were prepared in T25 culture flasks and returned to the
incubator for 1 h to allow agglomeration processes to occur. A 500 μL
amount of each nanoparticle dispersion at the concentrations stated in
the text were then loaded into capillary cells (#DTS1061, Malvern)
and analyzed with a ZetaSizer Nano ZS instrument (Malvern).
Samples were allowed to equilibrate at 37 °C for 2 min prior to size
(hydrodynamic diameter) and surface charge (zeta potential)
measurement. Size measurements were calculated from the average
of ten 100 s scans; charge measurements, from the average of ten 10 s
scans, with all DLS analyses repeated in duplicate from independently
prepared dispersions. Media controls (i.e., dispersants without
nanoparticles) were also included in all size analyses to ensure
nanoparticles were reliably detected against the serum protein
background. The dielectric constant of NSCM/RSCM was assumed
to be 74.5, and Henry’s function was set at the Smoluchowski
approximation of F(κa) = 1.5. Number distributions by population
percentage were exported using the ZetaSizer software (v6.20,
Malvern).
Cell Viability and DNA Damage Studies. Cell viability and
chromosomal damage resultant from the 24 h nanoparticle exposures
were assessed by relative population doubling (RPD) analysis and the
cytokinesis blocked micronucleus assay using duplicated, satellite
cultures. On day 1, cultures were established at ∼2 × 105 cells/mL
(count 1) prior to nanoparticle exposure for 24 h, washing twice with
PBS, and leaving to recover for one cell cycle (17 h) (count 2), with 3
μg/mL cytochalasin B included in cultures for the micronucleus assay.
RPD (%) was calculated as (no. population doublings (PD) in treated
cultures/no. PDs in control cultures) × 100, where PD was defined as
(log 10(count 2/count 1))/log(2). Mitomycin C at 0.01 μg/mL
(#M7949, Sigma) was used as a positive control. Cells were prepared
for micronucleus analysis by resuspension in 0.56% potassium chloride
hypotonic solution, followed by 10 min of incubation in “fixative one”
(5:1:6 methanol−acetic acid−0.9% sodium chloride) at 4 °C. Cells
then underwent four 10 min changes of “fixative two” (5:1 methanol−
acetic acid; 4 °C) and were left in the final wash overnight. The
resultant fixative/cell suspension was pipetted onto polished slides,
which were allowed to air-dry prior to nuclear staining with 0.15 μg/
mL 4′,6-diamido-2-phenylindole (DAPI). The presence of micronuclei
in binucleated cells (three replicates, 2000 cells scored per replicate)
was assessed automatically using an Axioimager Z2 fluorescent
microscope (Carl-Zeiss) equipped with an automated stage using
the Metafer 4 software (MetaSystems). Micronucleated cells were
manually validated using the 100× objective.
Preparation of Sectioned Cells for Transmission Electron
Microscopy. All buffers in the following steps were 200 mM and
maintained pH 7.3. After 24 h of exposure to the 16 or 85 nm SiO2,
the TK6 cells were washed twice with PBS and fixed in 2.5% Millonig’s
buffered glutaraldehyde for 4 h at 4 °C (#R1314, Agar Scientific). Cells
were then postfixed in 1% phosphate-buffered osmium tetroxide for 2
h in the dark at 4 °C prior to dehydration through an aqueous ethanol
series (25%, 70%, 90%, (100% × 2)); then, two changes of 100%
propylene oxide were performed. Resin infiltration involved 90 min of
incubation in 1:1 medium resin (#T028, TAAB) to propylene oxide,
followed by overnight incubation in 100% resin at 4 °C, prior to
baking for 24 h in fresh resin. Embedded samples were sectioned on an
EM-UC7 ultramicrotome (Leica) using a 45° diamond knife
(Diatome) with sections picked up on 150 mesh copper grids
(#G2150C, Agar Scientific) and sputter coated with ∼10 nm of carbon
to enhance electron conductivity.
Transmission Electron Microscopy/X-ray Microanalysis.
TEM was carried out at 200 kV using a Tecnai F20 field emission
gun TEM (FEI) fitted with a high-angle annular dark field detector
(Fischione) and an INCA 350 EDX spectrometry system using an 80
mm2 silicon drift detector (Oxford Instruments). Images were
recorded using an Orius SC600A CCD camera (Gatan).
Statistical Analyses of Dose−Response Data. Response
significance relative to untreated control was assessed by pairwise
testing according to the framework laid out by Johnson et al.60 Briefly,
response data were assessed for homogeneity of variance and
distribution normality by Bartlett and Shapiro-Wilk tests, respectively,
after log10 transformation. If the transformed data passed these tests (p
> 0.05), comparisons to negative controls employed one-sided (MN)
or two-sided (cell viability) post hoc Dunnett’s tests with alpha set at
0.05. Data sets that failed either test (p < 0.05) were analyzed using the
nonparametric post hoc Dunn’s test. Statistical analyses were conducted
using the online tool DRSMOOTH via Swansea University’s Mutation
Analysis Informatic Tools Web site (MutAIT.org).61 Benchmark dose
(BMD) (i.e., nonlinear regression analysis) was carried out using the
combined BMD−covariate method described extensively in previous
work.62,63 Briefly, analyses were carried out using the freely available
PROAST package (http://www.proast.nl) in the R computing
environment. Dose−response data were analyzed using a nested
family of four-parameter exponential models recommended by the
European Food Safety Authority for the analysis of continuous toxicity
data.64,65 In each analysis, combined data sets (i.e., collected across
NSCM/RSCM serum environments) were analyzed using the factor
discriminating the subgroupings (i.e., serum environment) as a
covariate. Models were fitted iteratively with more complex models
with greater numbers of covariate-dependent parameters only accepted
if the difference in log-likelihood exceeded p < 0.05. In this way, it was
established which model parameters needed to be estimated for each
subgroup and which parameters could be considered as constants
across the subgroups of each combined data set.66 Interpolation from
the fitted BMD model permitted estimation of the dose (i.e., the
BMD) that can be expected to elicit the benchmark response (here, set
at a 50% decrease in cell viability). For the 16 nm SiO2 data set,
comparison of the dose−response established in RSCM to that
established in NSCM further allowed calculation of a relative potency
factor.67 This value describes the relative potency of administered
doses of the 16 nm SiO2 in the RSCM environment relative to that in
NSCM (full analysis presented in Figure S9).
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